Farui Sun*, Yuanjin Zhang*, Lijun Xu*, Songbai Li*, Xiang Chen*, Ling Zhang*, Yifan Wu†, Jun Li*
Oncology Research, Vol.26, No.4, pp. 655-664, 2018, DOI:10.3727/096504017X15119525209765
Abstract Although cisplatin has been shown to be an integral part of chemotherapy regimen in osteosarcoma (OS) treatment, toxicity issues and chemoresistance have hindered therapeutic development for OS. Exploring novel
combination therapy methods is needed to circumvent the limitations of cisplatin alone. The proteasome inhibitor MG132 has shown antitumor effects in many solid tumors. However, little is known about its effects in
combination with cisplatin in OS cells. In this study, we examined the effects of MG132 in combination with
cisplatin in human OS cells (MG-63 and HOS). MG132 and cisplatin were applied to OS cells,… More >
Login
Register
